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When evaluating the midpoint of self-reported glucose,
there is a positive correlation between respondents’ per-
ceptions and the objective measures of their diabetes
control (r = 0.434, p < 0.001). However, based on their
midpoint values, most of the patients (92%) overesti-
mated their level of control. Self-reported values for about
two-thirds of respondents (62%) differed from laboratory
results by a clinically relevant amount of more than 25%.
When evaluating respondents’ highest reported blood
glucose values rather than the midpoint of their range,
there was a slightly higher correlation, (r = 0.467, 
p < 0.001). More importantly, based on this comparison,
fewer respondents (69%) overestimated their level of
control. Only about one-third of respondents (36%) mis-
reported their glucose by more than 25%. CONCLU-
SION: Objective measures of diabetes control correlate
best with highest self-reported glucose. These ﬁndings
underscore the importance of obtaining frequent objec-
tive measures of average glucose control, and the need to
monitor glucose values at times of day when they might
be highest, rather than lowest. When it is necessary to
utilize self-reported data, researchers should realize that
the maximum of a self-reported range may most accu-
rately reﬂect true blood glucose levels.
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OBJECTIVES: To determine if medication adherence
differs when a combination sulfonylurea/metformin is uti-
lized versus each component separately. METHODS:
Diabetes mellitus (DM) is a chronic and progressive dis-
order that leads to signiﬁcant morbidity and mortality
and imposes a large economic burden on the health care
expenditures in the United States. Although there have
been major improvements and modiﬁcations in the diag-
nosis and treatment strategies of diabetes, it estimated
that one-third of patients suffering from diabetes are
undiagnosed, and hence untreated. The prevalence of dia-
betes has risen along with disease related complications
nationwide. Therefore, we decided to evaluate patient
care by analyzing Health Partners’ pharmacy and medical
claims databases for a period of 12 months to determine
our own standard of care by evaluating in-house data on
HbA1c and lipid proﬁles and compare it with the stan-
dards set forth by the NCQA required HEDIS measures.
A computer database search of pharmacy claims identi-
ﬁed diabetic patients taking oral diabetic agents, insulin
or a combination therapy from January 2001–December
2001 according to the Universal System Classiﬁcation
(USC) codes indicative of diabetic agents. Patients were
eligible for inclusion if in a 12-month period, they
received mono-therapy on Glucovance, or combination
therapy of sulfonylureas and metformin for at least three
months during the year. Adherence was deﬁned as having
received medication for a minimum of 80% of the
therapy’s duration. Lab claims for HbA1C values on these
members were collected as well. Results indicated that
members on Glucovance (n = 562) were more adherent
to therapy (55% vs 52%) than those on combination
therapy (n = 932). In terms of HbA1C control, 18.9% of
members adherent to Glucovance therapy had a HbA1C
value of <6.5mg/dl versus 16.6% of those adherent with
combination therapy. We hope to further explore these
initial ﬁndings.
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OBJECTIVE: This study used Georgia Medicaid claims
data to evaluate the quality of care among African Amer-
ican (Black) and Caucasian American (White) adults with
diabetes mellitus who are enrolled in the mandatory
Georgia Better Health Care (GBHC) primary care case
management program, a managed care delivery model.
METHODS: This cohort study evaluated the quality of
care in relationship to the risk (i.e. rate) of diabetes-
related complications and hospitalization using Georgia
Medicaid eligibility and provider claim data for the
period 1996–1998 (by Chi square and multivariate 
logistic regression statistics). Black and White Medicaid
beneﬁciaries with newly diagnosed diabetes in 1996 and
1997 were followed for a 12-month period since diabetes
diagnosis through year 1997 and year 1998, respectively,
according to claim histories. Diabetes diagnoses are based
on physician-reported news claims of type-2 diabetes
(ICD-9-CM codes 250.0–250.9). Quality of care was
based on adherence to American Diabetes Association
(ADA) recommendations. RESULTS: The results of this
investigation indicated poor adherence to ADA recom-
mendations. Among the 3514 Medicaid beneﬁciaries with
diabetes who were enrolled for the entire 12-month
period after the initial diagnosis, only 22%, 11%, 15%,
and 2% received the ADA annually recommended HbA1c
test, eye exam, lipid proﬁle, or any nephropathy tests,
respectively. Although similarly likely to receive HbA1c
and nephropathy tests, Blacks were less likely to receive
eye exams (p = 0.0347) and lipid proﬁles (p < 0.0001),
independent of such variables as age, gender, insulin
status, number of clinic visits, and health plan option. The
results also indicated that the 12-month hospitalization
rate among Black beneﬁciaries was 1.6 times higher than
the rate among White beneﬁciaries. CONCLUSIONS:
GBHC, currently the only health plan option for Medic-
aid beneﬁciaries, has not achieved quality standards or an
equitable system of care for Georgia Medicaid beneﬁcia-
ries with diabetes.
